THE HOXA9/DNA BINDING INHIBITORS: IMPACT ON GENE REGULATION OF DB1055 AND DB818 RELATIVELY TO HOXA9 KNOCKDOWN.

EHA Library, Marie-Helene David, 419861

DECIPHERING EARLY STEPS OF TP53 ABERRANT HUMAN LEUKEMOGENESIS

EHA Library, Karin Lind, 419862

DEVELOPMENT OF A CUSTOM NGS PANEL FOR MEASURABLE RESIDUAL DISEASE ASSESMENT IN ACUTE MYELOID LEUKEMIA

EHA Library, Guillermo Ramil López, 419863

GERMLINE VARIANT DISCOVERY AND PATHOGENICITY EVALUATION IN HEMATOLOGICAL DISEASES HIGHLIGHTS THE ROLE OF CHEK2 VARIANTS

EHA Library, Outi Kilpivaara, 419864

COMPUTATIONAL MEASURABLE RESIDUAL DISEASE ASSESSMENT IN ACUTE MYELOID LEUKEMIA USING MIXTURE MODELS

EHA Library, Tim Mocking, 419865

CEPHALOCHROMIN-INDUCED MITOCHONDRIAL METABOLISM DOWNREGULATION OVERCOMES VENETOCLAX RESISTANCE IN DIVERSE ACUTE MYELOID LEUKEMIA MODELS

EHA Library, Mariane Cristina Do Nascimento, 419866

CEBPA ISOFORMS DIFFERENTIALLY CONTROL INFLAMMATORY TRANSCRIPTIONAL PROGRAMS

EHA Library, Maria Cadefau, 419867

GILTERITINIB VERSUS SALVAGE CHEMOTHERAPY IN MAINLY ASIAN PATIENTS WITH RELAPSED/REFRACTORY FLT3-MUTATED ACUTE MYELOID LEUKEMIA: REGIONAL SUB-ANALYSIS OF COMMODORE IN CHINA, SOUTH-EAST ASIA, RUSSIA

EHA Library, Jianxiang Wang, 419868

VENETOCLAX COMBINED WITH FLAG-IDA (FLAVIDA) IN REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA (R/R-AML)

EHA Library, Kai Wille, 419869

MULTICENTRE REAL-WORLD OUTCOMES FOR PATIENTS TREATED WITH VENETOCLAX AND AZACITIDINE FOR ACUTE MYELOID LEUKAEMIA IN THE NORTH OF ENGLAND

EHA Library, Nuno Borges, 419870

CLINICAL CHARACTERISTICS OF ACUTE LEUKEMIA WITH PICALM::MLLT10 FUSION IN ADULTS

EHA Library, Sankalp Arora, 419871

MYELOID NEOPLASMS IN OVARIAN CANCER PATIENTS TREATED WITH PARP INHIBITORS: REAL-LIFE EXPERIENCE FROM AN ONCOLOGY CENTER.

EHA Library, Rosario Custidiano, 419872

PREGNANCY OUTCOMES IN PATIENTS WITH ACUTE LEUKEMIA DIAGNOSED AT DIFFERENT GESTATION AGES: A MORE THAN 30 YEARS NATIONAL RESEARCH GROUP FOR THE TREATMENT OF ACUTE LEUKEMIA EXPERIENCE.

EHA Library, Vera Troitskaya, 419873

INCIDENCE AND OUTCOME OF ACUTE MYELOID LEUKEMIA WITH T(8;21)(Q22;Q22.2) – A DANISH NATIONWIDE POPULATION-BASED RETROSPECTIVE COHORT STUDY

EHA Library, Johannes Frasez Sørensen, 419874

TREATMENT PATTERNS AND OUTCOMES OF VENETOCLAX+HYPOMETHYLATING AGENTS VS HYPOMETHYLATING MONOTHERAPY IN PATIENTS ENROLLED IN MEDICARE ADVANTAGE WITH ACUTE MYELOID LEUKEMIA UNFIT FOR INTENSIVE THERAPY

EHA Library, Catherine Lai, 419875

IMPACT OF MALNUTRITION ON SURVIVAL AND CLINICAL OUTCOMES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC NEOPLASM: A COMPREHENSIVE ANALYSIS

EHA Library, Daniel Cabello Modesto, 419876

SAFETY OUTCOMES IN ADULT PATIENTS WITH AML WHO ACHIEVED THEIR FIRST COMPLETE REMISSION WITH GO PRIOR TO HSCT

EHA Library, Nelli Bejanyan, 419877

REAL-WORLD OVERALL SURVIVAL, TREATMENT PATTERNS, AND HEALTHCARE RESOURCE USE AMONG NEWLY DIAGNOSED UNFIT MEDICARE BENEFICIARIES WITH ACUTE MYELOID LEUKEMIA

EHA Library, Amer M. Zeidan, 419878

TIME TO HEMATOLOGIC RECOVERY IS A CRITICAL DETERMINANT OF COMPLETE REMISSION AS A SURROGATE FOR OVERALL SURVIVAL AFTER INTENSIVE CHEMOTHERAPY FOR ACUTE MYELOID LEUKEMIA

EHA Library, Rithin Nedumannil, 419879

A PHASE 1B/2 STUDY OF PIVEKIMAB SUNIRINE (PVEK, IMGN632) IN COMBINATION WITH VENETOCLAX/AZACITIDINE FOR PATIENTS WITH NEWLY DIAGNOSED CD123-POSITIVE ACUTE MYELOID LEUKEMIA

EHA Library, Naval Daver, 419881

SELINEXOR COMBINATION WITH DECITABINE AND HALF-DOSE CMG (CYTARABINE+ MITOXANTRONE+G-CSF) IN PATIENTS WITH R/R AML PREVIOUSLY EXPOSED TO VENETOCLAX：A SINGLE-CENTER RETROSPECTIVE STUDY

EHA Library, Zi-Yuan Nie, 419882

OUTCOMES WITH IMMUNE-BASED THERAPIES FOR TP53 MUTATED ACUTE MYELOID LEUKEMIA: A SYSTEMATIC REVIEW AND META-ANALYSIS

EHA Library, Moazzam Shahzad, 419883

CLINICAL PHARMACOLOGY AND PHARMACOKINETIC PROFILE OF ZIFTOMENIB, A MENIN INHIBITOR, IN ADULTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA

EHA Library, Amitava Mitra, 419884

CLINICAL OUTCOMES OF RELAPSED AND/OR REFRACTORY ACUTE MYELOID LEUKEMIA AFTER TREATMENT WITH GILTERITINIB

EHA Library, Elizabeth Corley, 419885

SINGLE-CENTER EXPERIENCE OF DECITABINE AND VENETOCLAX IN NEWLY DIAGNOSED OLDER AML PATIENTS WITH NON-FAVORABLE GENETICS: BRIDGING TO ALLO-HCT OR TREATMENT CONTINUATION

EHA Library, David Alber, 419886

UPDATES FROM A SINGLE-CENTER PHASE 2 STUDY OF PD-1 INHIBITOR COMBINED WITH DNA HYPOMETHYLATION AGENT + CAG REGIMEN IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA

EHA Library, Xiao-Ning Gao, 419887

INCIDENCE, PROGNOSTIC IMPACT AND NGS-BASED MRD ASSESSMENT OF ASXL2 MUTATIONS IN ACUTE MYELOID LEUKEMIA

EHA Library, Henri C. Hupe, 419888

SELINEXOR AND CHIDAMIDE TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA EXPOSED TO VENETOCLAX: A SINGLE-ARM, PHASE 2 STUDY

EHA Library, Jian Zhang, 419889

FLT3-ITD MICROCLONES ARE DETECTED AT RELAPSE IN PATIENTS WITH FLT3-ITD AML AFTER INTENSIVE CHEMOTHERAPY

EHA Library, Zhi Han Yeoh, 419890

REAL WORLD ANALYSIS OF CPX-351 VS 7+3 INDUCTION IN ACUTE MYELOID LEUKEMIA-MYELODYSPLASIA RELATED (AML-MR) IN PATIENTS (PTS) <60 YEARS (Y): AN ANALYSIS FROM MARROW CONSORTIUM

EHA Library, Daniel Peters, 419891

REAL-WORLD TREATMENT PATTERNS AND OUTCOMES WITH ORAL AZACITIDINE MAINTENANCE THERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA IN CANADA

EHA Library, Brian Leber, 419892

TREATMENT PATTERNS AND MOLECULAR TESTING ACROSS THE PATIENT JOURNEY: A REAL-WORLD ANALYSIS IN A U.S.-BASED COHORT OF NEWLY DIAGNOSED AND RELAPSED/REFRACTORY AML PATIENTS

EHA Library, Amer M. Zeidan, 419893

THE PREVALENCE AND PROGNOSTIC SIGNIFICANCE OF SOMATIC GENE MUTATIONS AMONG DE NOVO ACUTE MYELOID LEUKAEMIA PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS.

EHA Library, Shehab Fareed Abdelgabber, 419894

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION BRINGS SURVIVAL BENEFIT IN PATIENTS WITH ASXL1 MUTATED ACUTE MYELOID LEUKEMIA IN FIRST COMPLETE REMISSION

EHA Library, Mohamed Kawari, 419895

REAL-WORLD USE OF FIRST-LINE MIDOSTAURIN IN FLT3-MUTATED ACUTE MYELOID LEUKEMIA: A MULTICENTRIC STUDY FROM THE GRUPO PORTUGUÊS DE LEUCEMIAS AGUDAS

EHA Library, Joana Infante, 419897

PATIENT CHARACTERISTICS, BURDEN OF DISEASE AND HEALTHCARE UTILIZATION IN ACUTE MYELOID LEUKEMIA – AN ANALYSIS OF GERMAN CLAIMS DATA

EHA Library, Moritz Lehne, 419898

INTEGRATIVE ANALYSIS OF IMMUNE CHECKPOINT MOLECULES EXPRESSION DEFINES DISTINCT PROGNOSTIC CLUSTERS IN AML PATIENTS

EHA Library, Milan Jagurinoski, 419899

CONCOMITANT MUTATION OF DNA METHYLATION RELATED GENES PREDICTED A SUBTYPE OF ASXL1-MUTATED ACUTE MYELOID LEUKEMIA

EHA Library, Cai Yiming, 419900

MUTATIONS IN THE RUNX1 GENE IN AML PATIENTS.

EHA Library, Natali Severina, 419901

TREATMENT OUTCOMES FOR PATIENTS WITH BCOR-MUTATED ACUTE MYELOID LEUKEMIA

EHA Library, Ryan Jackson, 419902

PATIENT-CENTERED GENOMIC DIAGNOSTIC TESTING FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA: A QUALITY IMPROVEMENT PROJECT

EHA Library, Jenny Ho, 419903

IRON-RELATED LABORATORY PROFILE MAY PREDICT SURVIVAL, RISK OF INFECTION AND TRANSFUSIONAL NEED IN ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH INTENSIVE AND NON-INTENSIVE THERAPY REGIMENS

EHA Library, Federico Zingarelli, 419904

THE ROLE OF ALLO-HSCT IN AML CR1 PATIENTS WITH MRD NEGATIVITY AFTER THE FIRST INDUCTION COURSE

EHA Library, Elena Parovichnikova, 419905

DECITABINE PRIMING WITH CYTARABINE FOLLOWED BY UCB INFUSION AFTER VA THERAPY IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA : A SINGLE-CENTRE RETROSPECTIVE ANALYSIS

EHA Library, Li Ye, 419906

A MAXIMUM SINGLE DOSE OF ALLOGENEIC CAR-NK INFUSION IN AN ACUTE MYELOCYTIC LEUKEMIA PATIENT

EHA Library, Li Zhou, 419907

OUTCOMES AMONG NON-WESTERN IMMIGRANT PATIENTS AND DANISH-BORN PATIENTS WITH ACUTE MYELOID LEUKEMIA: A DANISH POPULATION-BASED COHORT STUDY

EHA Library, Daniel Tuyet Kristensen, 419908

ADVANCING THE UNDERSTANDING OF BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN) THROUGH INTERNATIONAL COLLABORATION: ANALYSIS OF 62 PATIENTS’ DATA FROM THE BPDCN GLOBAL REGISTRY

EHA Library, Astghik Voskanyan, 419909

COMBINATION OF MITOXANTRONE HYDROCHLORIDE LIPOSOME WITH CYTARABINE IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED AML: PHARMACOKINETICS, SAFETY AND EFFICACY

EHA Library, Wenyu Yang, 419910

IMPROVED CARE-PATHWAY CAN INCREASE THE OVERALL SURVIVAL AMONG ACUTE MYELOID LEUKAEMIA PATIENTS: A POPULATION-BASES STUDY USING DOUBLY ROBUST CAUSAL INFERENCE METHODS.

EHA Library, Kueshivi Midodji ATSOU, 419911

VALIDATION OF OPTICAL GENOME MAPPING AS A POTENTIAL STANDARD OF CARE CYTOGENOMIC METHODOLOGY IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Joanna Kamaso, 419912

PLCG2 Δ20-22 EXON-SKIPPED VARIANTS IN PRIMARY CLL

EHA Library, Jialei Qi, 419913

CODING AND REGULATORY REGIONS AFFECTED BY 17P AND 11Q DELETIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Romana Nesnadná, 419914

GENE POLYMORPHISM AND PRIMARY MULTIPLE METACHRONIC TUMORS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND MULTIPLE MYELOMA

EHA Library, Elena Nazarova, 419915

CYTOGENOMIC RESPONSE EVOLUTION IN TREATED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS USING OPTICAL GENOME MAPPING AND NEXT-GENERATION SEQUENCING

EHA Library, Rocío García-Serra, 419916

CHARACTERIZATION OF CD38 EXPRESSION IN T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PLL) PATIENTS: A SINGLE-CENTER EXPERIENCE OF 20 CASES

EHA Library, Giulia Calabretto, 419917

PREDICTING CLINICAL RESPONSE OF NON-HODGKIN LYMPHOMA WITH AN EX VIVO TUMOR MICROENVIRONMENT MODEL

EHA Library, Shazia Nakhoda, 419918

DISTINCT PATTERNS OF IN VIVO CLASS SWITCH RECOMBINATION EVENTS IN DIFFERENT IMMUNOGENETIC SUBGROUPS OF CLL: IMPLICATIONS FOR DISEASE ONTOGENY

EHA Library, Electra Sofou, 419919

OUTCOMES OF EPIC: A NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA TREATED WITH FIRST-LINE ACALABRUTINIB VIA THE UK EARLY ACCESS PROGRAMME; INTERIM ANALYSES.

EHA Library, Nicolas Martinez-Calle, 419920

PATIENT-REPORTED OUTCOME (PRO)–BASED RECURRENT SYMPTOMATIC DETERIORATION PREDICTS DISEASE PROGRESSION: RESULTS FROM THE ALPINE TRIAL

EHA Library, Jennifer R. Brown, 419921

CROSS-STUDY COMPARISON OF IBRUTINIB PLUS VENETOCLAX (I+V) VS VENETOCLAX PLUS OBINUTUZUMAB (V+G) IN SUBJECTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH COMORBIDITIES

EHA Library, Francisco Javier Lopez Jimenez, 419922

RISK OF HYPERTENSION IN PATIENTS WITH CLL/SLL WHO PARTICIPATED IN ALPINE: A POST HOC ANALYSIS

EHA Library, William B. White, 419923

POSTINFUSION RESOURCE USE AND COST OF LISOCABTAGENE MARALEUCEL BY RESPONSE STATUS AND PRIOR LINES OF THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA FROM TRANSCEND CLL 004

EHA Library, November McGarvey, 419924

IMPACT OF IGHV SUBSETS ON THE ROBUSTNESS OF DIFFERENT RISK SCORES TO PREDICT CLL PROGRESSION

EHA Library, Miguel Argüello de Tomás, 419925

UPDATED RESULTS OF COMBINATION TREATMENT WITH IBRUTINIB AND VENETOCLAX IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND COMPLEX KARYOTYPE: 4-YEAR FOLLOW-UP

EHA Library, Maria Kislova, 419926

RISK ADAPTED MANAGEMENT OF PATIENTS WITH EARLY-STAGE ASYMPTOMATIC CHRONIC LYMPHOCYTIC LEUKEMIA USING ACALABRUTINIB WITH OR WITHOUT OBINUTUZUMAB

EHA Library, Sameer Parikh, 419927

A PHASE II STUDY OF TIME-LIMITED TREATMENT WITH ACALABRUTINIB PLUS OBINUTUZUMAB IN PATIENTS WITH TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Jan Burger, 419928

REAL-WORLD EFFECTIVENESS OF VENETOCLAX-RITUXIMAB IN BTKI-NAÏVE AND BTKI-EXPERIENCED RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS IN BELGIUM

EHA Library, Sylvia Snauwaert, 419930

REAL-WORLD EVIDENCE STUDY OF PATIENTS TREATED FOR RELAPSED/REFRACTORY CLL WITH VENETOCLAX AND RITUXIMAB FOR A FIXED DURATION : AVENIR, A FRENCH MULTICENTRIC RETROSPECTIVE COHORT STUDY

EHA Library, Laemmel Lucie, 419931

REAL-WORLD FIRST LINE CHRONIC LYMPHOCYTIC LEUKEMIA TREATMENT IN GERMANY IN THE ERA OF TARGETED AGENTS

EHA Library, Zuzana Dostalova, 419932

REAL-WORLD CLINICAL OUTCOMES OF FIRST-LINE IBRUTINIB DOSE REDUCTION VERSUS ACALABRUTINIB AMONG PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA

EHA Library, Mazyar Shadman, 419933

RISK OF NEW-ONSET HYPERTENSION IN NEWLY DIAGNOSED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH BRUTON TYROSINE KINASE INHIBITORS: A REAL-WORLD STUDY USING THE SYMPHONY HEALTH SOLUTIONS DATABASE

EHA Library, William B. White, 419934

SAFETY AND EFFECTIVENESS OF CLL PATIENTS TREATED WITH VENETOCLAX IN COMBINATION WITH OBINUTUZUMAB OR RITUXIMAB UNDER REAL-WORLD CONDITIONS IN AUSTRIA, GERMANY, AND SWITZERLAND

EHA Library, Ingo Schwaner, 419935

PREDICTING PFS BENEFIT FROM CR RATES IN R/R CLL: A POOLED ANALYSIS OF RANDOMIZED CONTROLLED TRIALS (RCT)

EHA Library, Loïc Ysebaert, 419936

SAFETY AND EFFICACY OF IBRUTINIB IN INDIAN CLL PATIENTS WITH 17P DELETION.

EHA Library, Sujeet Kumar, 419937

PRELIMINARY SAFETY AND EFFICACY DATA FROM PATIENTS WITH RELAPSED OR REFRACTORY B-CELL MALIGNANCIES TREATED WITH ICP-248, A NOVEL BCL2 INHIBITOR.

EHA Library, Shuhua Yi, 419938

ACCELERATED CHRONIC LYMPHOCYTIC LEUKEMIA – THE CHARACTERISTICS AND RETROSPECTIVE ANALYSIS OF TREATMENT OUTCOMES IN POLISH HEMATOLOGY CENTERS

EHA Library, Bartosz Puła, 419939

INCIDENCE OF PNEUMONIA IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH VENETOCLAX-BASED REGIMENS: A REAL-WORLD ANALYSIS OF PALG, THE POLISH ADULT LEUKEMIA GROUP

EHA Library, Elżbieta Kalicińska, 419940

DIVERSIFYING CLINICAL TRIAL ENROLLMENT: DEVELOPING A NOVEL METHOD OF CLINICAL TRIAL SITE SELECTION TO IMPROVE CLINICAL TRIAL DIVERSITY

EHA Library, Brittaney-Belle Gordon, 419941

REAL-WORLD OUTCOMES OF ORELABRUTINIB AS FIRST-LINE TREATMENT IN CLL/SLL: A MULTICENTER STUDY

EHA Library, Huayuan Zhu, 419942

ANALYSIS OF OUTCOMES OF YOUNGER (≤ 55 YEARS) COMPARED WITH OLDER (> 55 YEARS) PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL)

EHA Library, TALBI FAIZA, 419943

A SENSIBLE AND SPECIFIC AUTOMATED SYSTEM FOR THE DETECTION OF DIFFERENT BCR::ABL1 REARRANGEMENTS IN PHILADELPHIA-POSITIVE LEUKEMIAS AT DIAGNOSIS

EHA Library, Stefania Stella, 419944

SOMATIC MUTATIONS IN CHRONIC MYELOID LEUKEMIA PATIENTS AFTER TYROSINE KINASE INHIBITORS TREATMENT FAILURE AND IN OPTIMAL RESPONSE.

EHA Library, Elena Kuzmina, 419945

IMPACT OF MOLECULAR RESPONSE DEPTH AT DISCONTINUATION AS A PROGNOSTIC FACTOR OF SUSTAINED TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKEMIA PATIENTS IN THE AST TRIAL.

EHA Library, Carolina Pavlovsky, 419946

COVID-19 IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: FINAL RESULTS FROM THE GLOBAL OBSERVATIONAL ICMLF CANDID STUDY

EHA Library, Delphine Rea, 419947

TYROSINE KINASE INHIBITOR WITHDRAWAL SYNDROME AND PSYCHOLOGICAL ISSUES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA AFTER THERAPY DISCONTINUATION

EHA Library, Mengyao Yuan, 419948

PATIENT REPORTED OUTCOMES IN ADULTS WITH TKI-RESISTANT CHRONIC MYELOID LEUKEMIA RECEIVING OLVEREMBATINIB-THERAPY

EHA Library, Lu Yu, 419949

TKI-FREE INTERVAL (TFI) FOR SAFE NAVIGATION OF PLANNED PREGNANCY IN NON-TFR ELIGIBLE FEMALE CML PATIENTS.

EHA Library, Sujeet Kumar, 419950

CLINICAL AND LABORATORY CHARACTERISTICS OF PATIENTS WITH RARE BCR::ABL1 FUSION TRANSCRIPTS

EHA Library, Yanbo Nie, 419951

ASCIMINIB (ASC) IS WELL TOLERATED IN PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): INTERIM PHARMACOKINETICS AND SAFETY RESULTS FROM ASC4KIDS

EHA Library, Nobuko Hijiya, 419952

COMPARISON OF EARLY TREATMENT RESPONSE & SAFETY OF LOWER DOSE (70 MG/DAY) VERSUS STANDARD DOSE (100 MG/DAY) OF GENERIC DASATINIB IN CHRONIC PHASE CML: RANDOMIZED CONTROLLED STUDY FROM INDIA

EHA Library, Paras Satadeve, 419953

RESULTS OF THERAPY OF ASCIMINIB AND PONATINIB IN CHRONIC MYELOID LEUKEMIA PATIENTS WITH FAILURE TO MORE THAN 2 TYROSINE KINASE INHIBITORS AND / OR BCR::ABL1 T315I MUTATION

EHA Library, Ekaterina Chelysheva, 419954

DELINEATING THE PATHOGENIC POTENTIAL OF DEAD-BOX ATP-DEPENDENT RNA HELICASE 41 GENE (DDX41) GERMLINE MUTATIONS IN HEREDITARY MYELOID NEOPLASMS

EHA Library, Marwa Almosailleakh, 419955

IMPACT OF NICHE CELLS IN THE PROGRESSION OF MDS TO SECONDARY AML

EHA Library, Mireia Atance Pasarisas, 419956

UNVEILING EPIGENETIC DYNAMICS: OXFORD NANOPORE SEQUENCING REVEALS GENOME-WIDE DNA METHYLATION PATTERNS IN CD34+ CELLS OF HR-MDS PATIENTS UNDERGOING ORAL AZACITIDINE THERAPY

EHA Library, Sven De Pourcq, 419957

MONOCYTES FROM PATIENTS WITH MYELODYSPLASTIC SYNDROME INHIBIT NK CELL-MEDIATED ANTI-TUMOR FUNCTION THROUGH THE CD200/CD200R PATHWAY

EHA Library, Zhaoyun Liu, 419958

CHARACTERIZING GENE EXPRESSION CHANGES IN MYELODYSPLASTIC SYNDROME PATIENTS WITH MUTATIONS IN COHESIN SUBUNIT STAG2 AT BULK AND SINGLE CELL RESOLUTION

EHA Library, Shubhra Ashish Bhattacharya, 419959

DETECTION OF PATHWAY ACTIVITY IN CELLULAR PROCESSES

EHA Library, Priyansh Srivastava, 419960

PROTEASOME PROTEOLYTIC ACTIVITY AND OTHER MARKERS OF RED BLOOD CELL PHYSIOLOGY AS INDICATORS OF DISEASE RISK AND THERAPEUTIC INTERVENTION IN MYELODYSPLASTIC SYNDROMES

EHA Library, Pinelopi Vryttia, 419961

MOUSE PDX MODELS TO EXPLORE DUAL RESISTANCE OF PROGRESSING MDS/AML TO 5-AZACYTIDINE AND VENETOCLAX.

EHA Library, Tomas Stopka, 419962

VULNERABILITY OF CSNK1A1 MUTATIONS TO FERROPTOSIS IN DEL(5Q) MYELODYSPLASTIC SYNDROMES

EHA Library, Stephani Schmitz, 419963